List of Contract Research Companies in Denmark - 4

ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase III-stage COVID-19 vaccine, ABNCoV2, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. The cVLP and ExpreS2 TM platforms are also basis for a proprietary HER2-cVLP breast cancer vaccine, ES2B-C001, which has proven preclinical proof of concept and is on path towards clinical investigations. The development pipeline also has projects based on the ExpreS2 platform alone, including multiple clinical-stage malaria vaccine projects sponsored by academic partners, as well as novel preclinical-stage influenza and CMV vaccines, the latter in a research collaboration with Evaxion Biotech. Since founded in 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. The cVLP platform resides in its 34%-owned associated company AdaptVac that was founded in 2017. ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq First North Growth Market, Stockholm (Ticker: EXPRS2).

At Fertin Pharma we specialize in the development and manufacturing of oral and intra-oral dosage formats. Our mission – Supporting Healthier Living – is carried out through our continuous desire to create the most innovative and consumer-friendly consumer healthcare products in the market. With an innovative and global profile, we engage in successful partnerships with leading pharmaceutical & nutraceutical companies. Supported by an experienced Research & Development team, extensive expertise in sensory optimisation and advanced manufacturing facilities, we support our customers from product formulation development to testing, manufacturing and regulatory compliance in order to ensure a smooth market launch. With a history dating all the way back to 1915, we have accumulated vast expertise and know-how within the field of chewing gum and other delivery formats. This knowledge is the foundation of our company, and it supports our vision of being the world’s leading supplier of pleasurable and convenient oral delivery systems. Fertin is also focused on the advancement in the science of Nicotine. For this reason we have started the Nicotine Science Center, which contributes with scientific insight into nicotine and its delivery. Visit the Nicotine Science Center Website. Copy this link into your browser: www.nicotinesciencecenter.com

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/

Tailwind Biotech is a biotech company offering synthetic DNA design services for improved strain development. We use proprietary Artificial Intelligence to help bioproduction-based companies worldwide achieve more effective and more efficient genetic engineering processes. Our technology designs optimized DNA sequences that help to maximize biological manufacturing yields while reducing development costs. We believe that by leveraging the powerful mix of Artificial Intelligence and Synthetic Biology, we can accelerate advancements in healthcare, agriculture, sustainable energy and beyond.